Textural features in pre-treatment [F18]-FDG-PET/CT are correlated with risk of local recurrence and disease-specific survival in early stage NSCLC patients receiving primary stereotactic radiation therapy

BackgroundTextural features in FDG-PET have been shown to provide prognostic information in a variety of tumor entities. Here we evaluate their predictive value for recurrence and prognosis in NSCLC patients receiving primary stereotactic radiation therapy (SBRT).Methods45 patients with early stage NSCLC (T1 or T2 tumor, no lymph node or distant metastases) were included in this retrospective study and followed over a median of 21.4 months (range 3.1–71.1). All patients were considered non-operable due to concomitant disease and referred to SBRT as the primary treatment modality. Pre-treatment FDG-PET/CT scans were obtained from all patients. SUV and volume-based analysis as well as extraction of textural features based on neighborhood gray-tone difference matrices (NGTDM) and gray-level co-occurence matrices (GLCM) were performed using InterView Fusion™ (Mediso Inc., Budapest). The ability to predict local recurrence (LR), lymph node (LN) and distant metastases (DM) was measured using the receiver operating characteristic (ROC). Univariate and multivariate analysis of overall and disease-specific survival were executed.Results7 out of 45 patients (16%) experienced LR, 11 (24%) LN and 11 (24%) DM. ROC revealed a significant correlation of several textural parameters with LR with an AUC value for entropy of 0.872. While there was also a significant correlation of LR with tumor size in the overall cohort, only texture was predictive when examining T1 (tumor diameter < = 3 cm) and T2 (>3 cm) subgroups. No correlation of the examined PET parameters with LN or DM was shown.In univariate survival analysis, both heterogeneity and tumor size were predictive for disease-specific survival, but only texture determined by entropy was determined as an independent factor in multivariate analysis (hazard ratio 7.48, p = .016). Overall survival was not significantly correlated to any examined parameter, most likely due to the high comorbidity in our cohort.ConclusionsOur study adds to the growing evidence that tumor heterogeneity as described by FDG-PET texture is associated with response to radiation therapy in NSCLC. The results may be helpful into identifying patients who might profit from an intensified treatment regime, but need to be verified in a prospective patient cohort before being incorporated into routine clinical practice.

[1]  Chun-Ta Liao,et al.  Textural Features of Pretreatment 18F-FDG PET/CT Images: Prognostic Significance in Patients with Advanced T-Stage Oropharyngeal Squamous Cell Carcinoma , 2013, The Journal of Nuclear Medicine.

[2]  H. Groen,et al.  18F-FDG PET during stereotactic body radiotherapy for stage I lung tumours cannot predict outcome: a pilot study , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  M Schwaiger,et al.  PET/CT Biograph Sensation 16. Performance improvement using faster electronics. , 2006, Nuklearmedizin. Nuclear medicine.

[4]  F. O’Sullivan,et al.  Spatial Heterogeneity in Sarcoma 18F-FDG Uptake as a Predictor of Patient Outcome , 2008, Journal of Nuclear Medicine.

[5]  Toshio Ohashi,et al.  The maximum standardized uptake value (SUVmax) on FDG-PET is a strong predictor of local recurrence for localized non-small-cell lung cancer after stereotactic body radiotherapy (SBRT). , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[6]  F. Brooks,et al.  The Effect of Small Tumor Volumes on Studies of Intratumoral Heterogeneity of Tracer Uptake , 2014, The Journal of Nuclear Medicine.

[7]  I. Buvat,et al.  Partial-Volume Effect in PET Tumor Imaging* , 2007, Journal of Nuclear Medicine.

[8]  Florent Tixier,et al.  Visual Versus Quantitative Assessment of Intratumor 18F-FDG PET Uptake Heterogeneity: Prognostic Value in Non–Small Cell Lung Cancer , 2014, The Journal of Nuclear Medicine.

[9]  Irène Buvat,et al.  Tumor Texture Analysis in 18F-FDG PET: Relationships Between Texture Parameters, Histogram Indices, Standardized Uptake Values, Metabolic Volumes, and Total Lesion Glycolysis , 2014, The Journal of Nuclear Medicine.

[10]  Michael Molls,et al.  Stereotactic radiotherapy of histologically proven inoperable stage I non-small cell lung cancer: patterns of failure. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  Ronald Boellaard,et al.  Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDG uptake in non-small cell lung cancer PET studies , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  R. Timmerman,et al.  FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer. , 2005, Lung cancer.

[13]  Aaron D Ward,et al.  Early prediction of tumor recurrence based on CT texture changes after stereotactic ablative radiotherapy (SABR) for lung cancer. , 2014, Medical physics.

[14]  S. T. Astner,et al.  Positron-emission tomography CT to identify local recurrence in stage I lung cancer patients 1 year after stereotactic body radiation therapy , 2013, Strahlentherapie und Onkologie.

[15]  E. Yorke,et al.  Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy. , 2014, International journal of radiation oncology, biology, physics.

[16]  D. Heron,et al.  Pretreatment SUVmax predicts progression-free survival in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy , 2014, Radiation Oncology.

[17]  Jan-Jakob Sonke,et al.  Modeling local control after hypofractionated stereotactic body radiation therapy for stage I non-small cell lung cancer: a report from the elekta collaborative lung research group. , 2012, International journal of radiation oncology, biology, physics.

[18]  Vicky Goh,et al.  Are Pretreatment 18F-FDG PET Tumor Textural Features in Non–Small Cell Lung Cancer Associated with Response and Survival After Chemoradiotherapy? , 2013, The Journal of Nuclear Medicine.

[19]  C. Reddy,et al.  Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy. , 2010, International journal of radiation oncology, biology, physics.

[20]  John Cho,et al.  Stereotactic body radiotherapy (SBRT) for non-small cell lung cancer (NSCLC): is FDG-PET a predictor of outcome? , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[21]  Suresh Senan,et al.  Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. , 2012, The Lancet. Oncology.

[22]  V. Goh,et al.  Non-small cell lung cancer: histopathologic correlates for texture parameters at CT. , 2013, Radiology.

[23]  E. Oermann,et al.  CyberKnife radiosurgery for inoperable stage IA non-small cell lung cancer: 18F-fluorodeoxyglucose positron emission tomography/computed tomography serial tumor response assessment , 2010, Journal of hematology & oncology.

[24]  Tomio Inoue,et al.  Deep-inspiration breath-hold PET/CT versus free breathing PET/CT and respiratory gating PET for reference: evaluation in 95 patients with lung cancer , 2011, Annals of nuclear medicine.

[25]  E. Kunieda,et al.  Maximum Standardized Uptake Value on FDG-PET Is a Strong Predictor of Overall and Disease-Free Survival for Non–Small-Cell Lung Cancer Patients after Stereotactic Body Radiotherapy , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[26]  M. Hatt,et al.  Intratumor Heterogeneity Characterized by Textural Features on Baseline 18F-FDG PET Images Predicts Response to Concomitant Radiochemotherapy in Esophageal Cancer , 2011, The Journal of Nuclear Medicine.

[27]  M. Hatt,et al.  Reproducibility of Tumor Uptake Heterogeneity Characterization Through Textural Feature Analysis in 18F-FDG PET , 2012, The Journal of Nuclear Medicine.

[28]  Makoto Kajihara,et al.  Differentiation of tumor recurrence from radiation-induced pulmonary fibrosis after stereotactic ablative radiotherapy for lung cancer: characterization of 18F-FDG PET/CT findings , 2013, Annals of Nuclear Medicine.

[29]  John Cho,et al.  Stereotactic body radiotherapy for medically inoperable lung cancer: prospective, single-center study of 108 consecutive patients. , 2012, International journal of radiation oncology, biology, physics.

[30]  F. Sterzing,et al.  Safety and Efficacy of Stereotactic Body Radiotherapy for Stage I Non–Small-Cell Lung Cancer in Routine Clinical Practice: A Patterns-of-Care and Outcome Analysis , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[31]  Vicky Goh,et al.  Quantifying tumour heterogeneity in 18F-FDG PET/CT imaging by texture analysis , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[32]  Ross Berbeco,et al.  Comparison of Texture Features Derived from Static and Respiratory-Gated PET Images in Non-Small Cell Lung Cancer , 2014, PloS one.